Clinical Trial

Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction

Study acronym: DAPA-STEMI
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2025 (before its estimated March 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The DAPA-STEMI trial investigates whether dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), reduces heart muscle scarring (fibrosis) and improves heart function after a ST-segment elevation myocardial infarction (STEMI). The trial will use cardiac MRI to measure changes in heart structure and function over six months. Patients aged 30-85 who have had a recent STEMI will receive either dapagliflozin or a placebo. The study aims to provide mechanistic insights into heart failure prevention after heart attacks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-27.
Trial Details
NCT Number NCT06619600
Lead Sponsor Hospital Clinic of Barcelona
Conditions ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Heart Failure, Myocardial Fibrosis
Enrollment 54 participants
Start Date 2021-05-30
Primary Completion 2025-03-31 (estimated)
Study Completion 2025-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-19